Chai Discovery closed a $130 million Series B to accelerate development of its Chai‑2 generative platform for de novo antibody design and to expand commercialization, the company announced. The Bay Area startup said Chai‑2 achieved double‑digit experimental success rates and scaled design‑to‑wet‑lab validation to under two weeks, claims detailed in recent preprints and press releases. Investors including Oak HC/FT and General Catalyst led the round; the funding follows a $70 million Series A earlier in 2025. Chai’s public preprints report multivalent benchmarks—16% success in small de novo screens and >86% developability for full‑length mAbs in extended datasets—data the company says underpin faster lead generation and hit rates versus legacy computational methods. CEO Josh Meier framed the raise as a bet on moving antibody discovery from iterative wet‑lab cycles toward an AI‑first design workflow. The company will use proceeds to scale compute, expand wet‑lab throughput, and commercialize design services for pharma partners.